Ruti Aga's Six-Year Ban: A Two-Year Case and a Four-Year Prescription

The clinic did not exist.

The doctor named on the prescription was a member of Aga's own family, with no medical registration attached to the name. Under questioning he said he had used "an old prescription pad from a former workplace." That former workplace, the clinic, publicly disowned the pad. Three verification failures inside one document: an institution that wasn't there, a signatory with no register entry, and a pad nobody would admit to issuing.

That is where Ruti Aga's case was decided. Not by methylprednisolone. By the prescription.

I opened the spreadsheet — not before a press box filled up this time, but in front of an Athletics Integrity Unit (AIU) statement. Six years for the Ethiopian marathoner, effective 10 September, the same date her provisional suspension had been running from. The number did not arrive out of nowhere. It is the sum of two parts, and each part has a reason. The reporting that carried the story gave the total and not the arithmetic. The arithmetic is my job.

What the record leaves out is also data

Aga is 32. She won the 2026 Tokyo Marathon, a World Marathon Major title. From external recall — and I am flagging this clearly as not present in the source and pending verification — her Berlin 2026 run was 2:18:34 for second, and Tokyo 2026 was 2:20:40 for the win. Three second-place finishes at Majors, again external to the source.

What the source contains is narrower: a positive sample after winning a half marathon in China in March; a knee injury cited as the reason for a methylprednisolone injection; a prescription that was manufactured; and six years.

The race is unnamed. The mark is absent. The field quality is absent. The year of the March race is absent. The scope of disqualification is absent. There is not one line from the Ethiopian federation — the only quoted body is the AIU.

That gap is not a hole in my reporting; it is the shape of the case. And with no mark in hand, any claim about her form would be fiction. What can be written is that she won the race, which tells us it was a field with in-competition testing. Nothing more.

S9 versus S1: the whole case turns on a classification

Here is my first correction, because the report that carried this story contains a technical error and it is not a small one.

That report called methylprednisolone a "prohibited steroid" and said WADA classes it as performance enhancing. Methylprednisolone is a glucocorticoid — WADA Prohibited List class S9 — not an anabolic steroid (class S1). And S9 carries a condition: prohibited in-competition only, and only by injection, oral or rectal routes. A therapeutic knee injection out of competition is entirely legal.

The consequence is direct: the hinge of this case is not "steroid use," it is route and timing. When the injection went in, by which route, and whether residues were still present on race day. A road race's testing window opens at 23:59 the day before, which means an injection given days earlier can still be caught. This is logistics, not medicine.

Which means Aga had a legitimate defence available. Real medical records, a real prescription, the injection date, the route, the knee pathology — with those, the argument that this was therapeutic use and the residue a timing error was open. It does not work in every case. It was open in this one.

She burned it. When you substitute a forged document for a genuine one, you are conceding that the genuine one either did not exist or did not help. A forged prescription is not merely a document; it is a confession.

The arithmetic: 2 + 4 = 6

The sanction architecture is standard, which is exactly why it is worth reading.

Two years for the presence violation — the period that corresponds to a Specified Substance finding without proven intent. Four years for tampering, the Code's standard penalty. The sum is six.

The real information is in what is missing from the sum. Had the panel accepted that the athlete bore no significant fault, the two-year presence sanction would have been cut. It was not. The panel rejected the no-significant-fault mitigation, and the reason it rejected was not methylprednisolone. It was the prescription.

There is an odd tension here: forged documentation is itself circumstantial evidence of concealment intent, yet it did not aggravate the presence sanction. The panel kept the two accounts separate — substance in one, document in the other. Technically clean. Morally strange.

Backdating to 10 September is not relief. Time served under provisional suspension counts against the ban; the athlete gains procedure, not reduction. The clock was already running.

32 to 38: the career arithmetic

Under the stopwatch every salary line becomes a performance claim. Here the stopwatch is a sanction ledger and the line is the same.

Six years at 32. Return age roughly 38. Look at Ethiopian women's marathon depth — world-record class at the top, multiple sub-2:16 and sub-2:14 performers underneath. A 38-year-old returnee with a doping record is effectively unselectable in that pool. On paper the ban is six years; in practice it is career termination.

One asset survives: the 2026 Tokyo title. The violation is anchored to a later March race, and absent a finding of earlier use, results before that date are not automatically annulled. The source does not state the disqualification scope. I will not fill that with inference — though disqualification of the race where the sample was collected, prize money included, is standard AIU practice even when the release does not use the word.

The root cause is a knee, not a prescription

Now the part where the data goes quiet and I have to open a qualitative column and label it as such.

Chronic knee pathology in distance running is not an exception, it is architecture. Synovitis in an athlete running 180–200 kilometres a week is the logical output of load, and intra-articular methylprednisolone is standard sports-medicine practice. Biologically it makes sense. Legally it proved fatal — not because the treatment was wrong, but because the treatment had no paper behind it.

What turns this from a story about individual ethics into a story about systems is the medical-support structure — or its absence. An athlete with a credentialed team physician chooses one of two paths: apply for a Therapeutic Use Exemption, or observe the WADA route-specific washout. Neither happened. What happened was a third path: a relative, an old pad, and a clinic that existed on paper and nowhere else.

I have to be careful here, because correlation is not causation. A knee injury and a forged prescription appearing in the same sentence does not prove the injury produced the forgery. But the direction is clear: the athlete had treatment, had no documentation, and nobody told her that treatment without documentation is a two-year case while forged documentation is a six-year one. Nobody in that entourage ran the arithmetic for her. That is the real failure.

The enforcement frontier has moved to documents

I do not trust a trend until I can reconcile it to the ledger — and the ledger says the four-year half of this case came from paper, not from a substance.

That matters. As detection probability rises, the centre of offending shifts: it used to be "what did you take," now it is "what did you explain." In AIU road-running cases there is a recognisable family where the first violation is small and the explanation is large. Aga's case belongs to that family; it is not an outlier. I am stating that as pattern recognition, not as a statistical finding — I have no clean dataset behind it, and what I do not have I will not claim.

The second implication sits in China's label-race circuit. For East African marathoners, that circuit is a high-appearance-fee, low-race-count income tier between Majors. It is also now the AIU's highest-yield testing ground. The appearance-fee economy and the testing economy are colliding in the same races, and that collision will produce more cases.

The third implication is the least comfortable: six years for a substance with no proven endurance benefit. That number will be cited from both directions — as proof of AIU rigour, and as proof of disproportionate enforcement against African road runners. My reading is that the four years were not about the substance. They were about the document. And a document is the hardest thing to defend.

Who was not charged

The AIU statement names one person: the family member. No agent. No manager. No training camp.

I am not saying they are culpable; I am saying whether they were investigated is not on the public record. Someone advised on that prescription, someone accepted it, someone put it in front of the AIU. A 32-year-old athlete does not decide alone how a document gets made. That is my inference and I will label it as one.

From the Ethiopian federation, not one sentence. That silence is data too, and I am filing it the way I file a split. The country with the deepest women's marathon pipeline in the world said nothing about a six-year ban on one of its Major winners — which tells us as much about the administrative structure as the prescription did.

The next signal

The next event is an appeal. The CAS window typically runs about 21 days from the reasoned decision, and a document-based forgery finding is very hard to overturn. What can move is the scope: whether the March result and its prize money are voided, whether ranking points accrued after that date are forfeited. The release does not say, and I will try to have it checked by morning.

The larger question is not whether Ruti Aga cheated. That is settled. It is what happens to the next 32-year-old with an inflamed knee and no doctor in her camp — whether she has a relative and an old pad, or a phone number that a credentialed physician picks up.

The day that answer changes, cases like this get rarer. Until then, the six-year arithmetic stands.